Sarcopenia is defined as an age-related loss of muscle mass and function, and is associated with frailty and reduced functional ability and independence,[@bib1], [@bib2], [@bib3] as well as increased incidence of falls, disability, infection, and mortality.[@bib1], [@bib4], [@bib5], [@bib6], [@bib7] Combined with the growing economic impact, demonstrated by US healthcare costs from 2000 which attribute \$18.5 billion to sarcopenia and associated health problems,[@bib8] sarcopenia is a serious public health issue. Interventions to maintain muscle mass in older adults are a major priority and would be expected to result in both improved quality of life in old age and decreased healthcare costs.

Although the design of effective interventions has been a major goal for 30 years, so far only resistance exercise has shown any real benefit in improving muscle mass in older people. In younger adults, resistance exercise has been shown to acutely sensitize skeletal muscle to the anabolic effects of ingested protein or essential amino acids (EAA).[@bib9], [@bib10] Hence, when considered in terms of a chronic response, resistance exercise training (RET) programs and nutritional supplementation (protein, EAA, or leucine) have an additive effect on muscle strength and fat free mass (FFM).[@bib11] One might assume, therefore, that an intervention combining RET and supplementation could be an effective strategy against sarcopenia in older adults, however, the presence of an effect in younger adults does not necessarily mean there will be an effect in older adults. The acute anabolic responsiveness to both resistance exercise and protein supplementation is blunted in older adults compared with younger adults,[@bib12], [@bib13] and this is thought to translate into a chronic blunting of responsiveness.[@bib14] Thus, it is plausible that the chronic response to a combination of these factors may also differ in older adults.

In spite of this anabolic blunting, previous reviews of studies in older adults have found chronic additive effects of RET and protein/EAA supplementation compared with RET only, in terms of FFM[@bib11], [@bib15] and muscle strength.[@bib11] However, there are issues with the relatively low minimum age limit inclusion criteria for these reviews; one used a cut-off of 50 years of age for the "older" age group, and the oldest participant included was 72 years of age, and in the other the lower age limit was an average of 60 years of age and included studies in which some participants were as young as 50 years of age. These age categories are not necessarily representative of older adults, and a cut-off mean 70 years of age may be more appropriate to define "elderly." Longitudinal evidence shows that muscle strength and power continue to decline into advanced older age,[@bib16] and a dramatic increase in the prevalence of sarcopenia has been observed in the eighth decade of life.[@bib5] Hence, it would appear that the muscle of people aged over 70 years is performing differently to that of those aged 50 or 60 years, meaning it is likely that the responsiveness to anabolic factors may also differ between these age ranges. This would mean that the inclusion of studies involving these relatively younger participants may mask any differences in the effects of the combined intervention on the truly older adults. The use of an older cut-off point to define older adults is supported by the studies demonstrating anabolic resistance,[@bib12], [@bib13] both of which reported an average age of 70 years, and is likely to give a better representation of the effect of anabolic resistance on chronic responsiveness to RET and protein supplementation. Furthermore, arguably the most important outcomes in terms of a practical impact of an intervention are those related to functional ability. Such outcomes are highly relevant to quality of life and the maintenance of an independent lifestyle, which are key priorities when setting lifestyle recommendations. To date, the combined effects of RET and protein supplementation on functional ability have yet to be addressed within a systematic review.

The aim of this systematic review was to determine whether protein or EAA supplementation can augment the effects of RET in older adults (ie, studies with an average age of 70 years or older). These effects included changes from baseline in muscle strength as the primary outcome, and secondary outcomes of muscle size, body composition, and indicators of functional ability, where functional ability was defined as the ability to perform everyday tasks and activities important for the maintenance of physical independence.

Methods {#sec1}
=======

The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) report.[@bib17] Although this protocol has not been previously published, all procedures were determined in advance.

Selection Criteria {#sec1.1}
------------------

Inclusion criteria were (1) controlled trials in humans implementing a progressive RET regimen in combination with a protein or EAA supplement, and inclusion of a comparison group combining RET with either a placebo/non-protein supplement or no supplement at all \[Studies comparing higher versus lower protein diets were accepted providing the low protein diet was equivalent to the US recommended daily allowance (RDA) for protein (0.8 g·kg^−1^·day^−1^)\][@bib18]; (2) studies including participants with a mean age of 70 years or over, both healthy and frail; (3) studies within any publication category and all languages; and (4) outcome measures including muscle strength (primary), muscle size, functional ability (defined as the ability to perform everyday tasks and activities important for the maintenance of physical independence), and body composition (secondary).

Studies were excluded if the intervention was administered with an agent previously shown to result in muscle gains (with the exception of vitamins and minerals), or if it was administered to a specific patient group or with the intention of treating a clinical condition other than frailty or sarcopenia.

Information Sources and Search {#sec1.2}
------------------------------

An electronic search of online databases was conducted in August 2015, using selected key words, "free text" terms, indexed terms, and Boolean operators ([Table 1](#tbl1){ref-type="table"}). Search strategies were constructed using search terms to identify papers on elderly populations with suitable supplementation and training regimens and a search filter to limit retrievals to studies in humans. The search strategies were applied to MEDLINE (1946 to August 2015); EMBASE (1980 to August 2015); CINAHL Plus (1937 to August 2015); SPORTDiscus (1949 to August 2015). Recursive searching of the bibliographies of eligible studies and relevant reviews was performed to identify additional studies.

Study Selection {#sec1.3}
---------------

Titles and abstracts were screened for relevance by 1 reviewer (D.T.). Clearly irrelevant titles were removed. Full-text papers were obtained for potentially relevant studies, via a combination of online databases and direct contact with the authors, and these were further evaluated to determine whether they met the inclusion criteria. Two reviewers (D.T. and C.G.) independently assessed full-texts for eligibility, with a third reviewer (D.S.) moderating if necessary. Studies deemed eligible were included in the systematic review.

Data Extraction {#sec1.4}
---------------

Data were extracted from each of the included papers using a standardized data extraction form. Details of interest included various aspects of study design, resistance training regimens, protein/EAA supplements, and the comparison treatment, as well as participant characteristics and baseline protein intake. Data were sought for outcomes of muscle strength, muscle size, functional ability, and body composition. Where necessary, the required data were interpolated from figures or calculated from the reported data. Corresponding authors were contacted if this information could not be obtained from the paper, and if data could not be obtained, the study (or outcome measure) was excluded from meta-analysis.

Quality Assessment {#sec1.5}
------------------

Methodologic quality of included studies was assessed using the Physiotherapy Evidence Database (PEDro) scale.[@bib19] A score of 6 or higher indicated moderate to high quality.

Summary Measures and Synthesis of Results {#sec1.6}
-----------------------------------------

Extracted data were collated and a review was conducted for the primary outcome (ie, muscle strength, as well as the secondary outcomes of muscle size, functional ability and body composition). This included description of studies and tabulation of data presented as mean \[standard deviation (SD)\] unless stated otherwise.

Meta-analysis was conducted on comparable outcomes reported in a minimum of 2 studies. Similar study protocols were a requisite for comparison using meta-analysis, and, despite all included studies addressing the questioned posed by this review, fundamental differences in their protocols meant that a number of study combinations were unsuitable for meta-analysis. Key criteria for determining study comparability included additional supplementation with vitamin D (which may also influence muscle related outcomes[@bib20]), the frequency of protein supplementation (ie, daily or only on training days), the timing of supplementation (including number of doses), and the amount of protein supplemented, with consideration also given to the type of protein supplemented and the duration of the study.

Results {#sec2}
=======

Study Selection {#sec2.1}
---------------

A total of 11,770 publications were identified by the literature search, of which 16 publications including 15 studies met all of the inclusion criteria and were included in the systematic review[@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36] ([Figure 1](#fig1){ref-type="fig"}). Two publications[@bib24], [@bib27] reported results from the Frail Older People-Activity and Nutrition Study in Umeå and, therefore, were considered here as 1 study.[@bib24]

Study Characteristics {#sec2.2}
---------------------

The 15 eligible studies included 917 participants with a mean age of 77.4 years (range 60--100 years) ([Table 2](#tbl2){ref-type="table"}). Six studies including 400 participants were conducted in older adults described as frail, sarcopenic, or mobility limited.[@bib21], [@bib24], [@bib26], [@bib28], [@bib29], [@bib31] Individuals in the remaining 9 studies were categorized as healthy.[@bib22], [@bib23], [@bib25], [@bib30], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36] Three studies included only male populations,[@bib22], [@bib25], [@bib35] 2 included female only populations,[@bib28], [@bib33] and the remaining 10 were mixed populations.[@bib21], [@bib23], [@bib24], [@bib26], [@bib29], [@bib30], [@bib31], [@bib32], [@bib34], [@bib36] Of the total participants, 32% were male and 68% were female. All studies were published in English.

Resistance exercise regimens varied in frequency from 2 to 5 occasions per week, with a mean (SD) of 3 (1) per week. Programs lasted between 7 weeks and 1 year, with a mean (SD) of 18 (11) weeks. All studies reported a progressive exercise regimen; 9 comprised both upper and lower limb training,[@bib25], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37] and 6 involved training of the lower limbs alone.[@bib23], [@bib24], [@bib26], [@bib27], [@bib28], [@bib38] In addition to resistance exercise, participants of 5 studies[@bib26], [@bib28], [@bib30], [@bib35], [@bib38] undertook co-interventions including functional and/or balance exercises ([Table 2](#tbl2){ref-type="table"}).

A total of 10 studies included daily protein supplementation,[@bib21], [@bib22], [@bib23], [@bib28], [@bib29], [@bib31], [@bib32], [@bib34], [@bib35], [@bib36] 1 included supplementation on 6 days per week,[@bib33] and in the remaining 4, participants received supplements only on the day of training.[@bib24], [@bib25], [@bib26], [@bib30] Baseline daily protein intake was reported in 8 studies[@bib22], [@bib25], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib36] ([Table 2](#tbl2){ref-type="table"}), giving a mean (SD) of 1.08 (0.07) g·kg^−1^·d^−1^ (range 0.97--1.24 g·kg^−1^·d^−1^). The amount of protein supplemented varied from 6 g per day to 45 g per day with a mean (SD) of 19 (11) g ([Table 2](#tbl2){ref-type="table"}). Eight supplemented groups[@bib24], [@bib25], [@bib29], [@bib30], [@bib31], [@bib32], [@bib34], [@bib35] received protein derived from milk (casein, whey, chocolate milk), 1 group received soy-based protein,[@bib21] 1 group was supplemented with lean red meat,[@bib33] 2 studies did not disclose the nature of the protein supplement,[@bib23], [@bib26] 2 groups received EAA,[@bib22], [@bib28] and 1 group received only leucine.[@bib36] Timing of ingestion was inconsistent; in 3 studies, the supplement was administered immediately after training[@bib22], [@bib24], [@bib30]; in 1 study administration was immediately before training[@bib26]; in 1 study one-half of the supplement was administered before training and half after[@bib25]; 8 studies administered supplements at a consistent time relative to meals[@bib21], [@bib23], [@bib28], [@bib29], [@bib31], [@bib32], [@bib33], [@bib36]; the 2 remaining studies used a combination of supplementation after meals and after training.[@bib34], [@bib35] In addition to protein, 6 studies also supplemented participants with vitamin D,[@bib21], [@bib23], [@bib26], [@bib33], [@bib34], [@bib35] with reported doses ranging from 2 to 25 μg and 2 doses given as approximate proportions of recommendations.

The studies were highly variable in terms of both study characteristics and outcome measures, and as a consequence, only 2 studies were sufficiently similar to be included in a meta-analysis. The results were, thus, inconclusive and are not reported here, although forest plots are available in [Supplementary File 1](#appsec1){ref-type="sec"}.

Study Quality {#sec2.3}
-------------

The median overall quality score derived using the Physiotherapy Evidence Database scale was 7/10 (range 4--10), and the median score for internal validity was 5/8 (range 2--8) ([Table 3](#tbl3){ref-type="table"}). All studies scored 2/2 for statistical reporting.

Effect of Intervention on Muscle Strength {#sec2.4}
-----------------------------------------

All 15 studies included in the systematic review included a measurement of muscle strength, although a number of different muscle groups were studied ([Table 4](#tbl4){ref-type="table"}). Eleven out of 15 studies demonstrated significant improvements from baseline in every measure of muscle strength in all groups undertaking RET with protein/EAA supplementation. Of the remaining studies, 1 demonstrated significant improvements in 6 of the 8 strength measurements included,[@bib26] 2 reported significant increases in all measurements except handgrip strength,[@bib29], [@bib32] and 1 measured only handgrip strength and reported no change.[@bib34] Three of the 15 studies reported significant differences between control and supplemented groups, with greater improvements in the supplemented groups in measures of knee extension strength[@bib28], [@bib33] and hand grip strength,[@bib23] and 1 study reported a trend for greater improvement in leg flexion strength.[@bib36]

Effect of Intervention on Secondary Outcomes {#sec2.5}
--------------------------------------------

### Muscle size {#sec2.5.1}

Eight studies investigated the effect of supplementation on muscle size ([Table 4](#tbl4){ref-type="table"}). Six studies measured thigh muscle cross-sectional area using computed tomography, another measured midarm, calf, and hip circumference, and the other measured midupper arm muscle area, triceps skinfold, and calf circumference. All but 1 of the studies which used computed tomography to measure cross-sectional area reported significant increases in both supplemented and nonsupplement groups, however, there were no significant differences between the groups. No changes were reported in any other measure of muscle size.

### Functional ability {#sec2.5.2}

At least 1 functional ability outcome was assessed in 12 out of the 15 included studies, with 27 outcomes assessed in total ([Table 4](#tbl4){ref-type="table"}). There was much heterogeneity among outcome measures, which included chair rise ability (6 studies), gait velocity (5 studies), walking capacity (4 studies), the Timed Up and Go (TUG) test (3 studies), balance tests (2 studies), stair climb speed (1 study), and the 4-square step test (1 study). Three studies included a "composite" of some of these physical performance indicators; 2 used the Short Physical Performance Battery (SPPB) which combines balance, gait speed, and chair rise ability,[@bib37] and 1 used Tinetti\'s Performance Oriented Mobility Assessment (POMA) test combining balance and gait.[@bib38] Of the 27 functional ability measurements, 21 were significantly improved after the intervention period, although none of these improvements were significantly different with protein/EAA supplementation compared with nonsupplemented controls.

### Body composition {#sec2.5.3}

Body composition was assessed in 9 studies ([Table 4](#tbl4){ref-type="table"}). Body composition was assessed using dual energy X-ray absorptiometry in all studies except 2; one of which used a segmental multifrequency bioelectrical impedance analysis technique, and the other used bioelectrical impedance spectroscopy. Measurements included total lean body mass (LBM) in 6 studies; total body fat mass (FM) in 6 studies; percentage FM in 3 studies; estimated total muscle mass (MM) in 2 studies; and FFM in 1 study. A number of studies also included regional measurements of body composition: leg lean tissue mass (LTM) in 3 studies; appendicular LTM in 2 studies; estimated appendicular MM in 1 study; estimated leg MM in 1 study; leg FM and percentage FM in 1 study; and arm LTM in 1 study. Of the 28 measurements of body composition, 6 demonstrated no significant change during the studies. Improvement in body composition with no difference between treatment groups was shown in 17 measurements, although within-group analysis of 2 of these measurements within 1 study indicated a significant decrease in total FM and body fat percentage in the protein supplemented group but not the control group.[@bib33] Five measurements from 2 studies indicated significant differences between groups,[@bib29], [@bib33] with greater increases in LBM, leg LTM, appendicular LTM, and FM in the supplemented groups compared with the exercise-only controls.

Discussion {#sec3}
==========

This systematic review presents evidence from 15 studies investigating the additive effects of RET and protein supplementation on skeletal muscle strength and size, body composition, and functional ability in older adults. Studies reported overall improvement from baseline for the majority of outcomes, indicating a positive effect of RET. However, across the 15 studies, these improvements were not significantly different in groups receiving protein/EAA supplements and undergoing RET compared with RET alone.

A previous systematic review has shown that older muscle demonstrates an adaptive response to RET across a range of outcomes,[@bib39] hence, RET alone is considered an effective strategy for combatting sarcopenia. Given the anabolic properties of both resistance exercise and protein/EAA ingestion, it is plausible that the combination of these factors in a chronic intervention may have an additive effect and so enhance the responses shown with RET alone. Certainly, this has been shown to be the case in younger adults,[@bib11] however, despite individual significant results in strength and body composition outcomes, the overall results of the present review indicate that this does not hold true for older adults.

This overall absence of an additive effect, in contrast to that of younger adults, may be a result of the mechanisms of anabolic resistance in older muscle. For example, the expression and activation of proteins responsible for EAA sensing and signaling are reduced in older people,[@bib13] meaning the extent to which the subsequent cascades can be activated is limited, causing a blunted anabolic response compared with younger adults. Thus, if the limit for activation has been reached, any increase in the upstream signal (ie, more amino acids) will not result in any additional response. Where reported, all baseline protein intakes were within the RDA, and with lower sensitivity to higher protein intakes, this may have been sufficient to elicit a maximal protein synthetic response in combination with RET, prior to any supplementation. Certainly, there is evidence to suggest that there is no benefit for older adults in consuming more than the RDA for protein; in a 12-week trial of adults aged 50--80 years, daily protein intake was increased from 0.9 g·kg^−1^·d^−1^ to 1.3 g·kg^−1^·d^−1^ with no additional response to RET.[@bib40] Furthermore, when the effects of consuming the RDA were compared with a higher protein dose in older adults performing RET, the metabolic adaptations to increased protein intake actually reduced the utilization of protein.[@bib41] However, data from a recent study in older men do indicate increased phosphorylation of the anabolic signaling molecule p70S6K, indicating a dose-response relationship in an acute setting.[@bib42] As this relationship does not appear to translate to a chronic setting, this suggests that the mechanisms of this anabolic effect require further investigation.

An alternative view suggests that older adults actually require more protein than their younger counterparts to protect against sarcopenia. Contrary to the current RDA of 0.8--1.2 g·kg^−1^·day^−1^, a recent evidence-based recommendation suggests an intake of 1.0--1.2 g·kg^−1^·day^−1^ would be more advisable.[@bib43] If the findings of this review are considered from this perspective, most included studies were above the lower limit of this recommendation, and so the idea that baseline intakes were sufficient to maximally stimulate MPS would still apply. However, baseline intakes in 2 studies, while meeting the RDA, were at or below the alternative recommendation,[@bib29], [@bib31] and the supplemented groups in these 2 studies saw the greatest increase in protein intake relative to baseline. One of these studies also fell into the small number, which found a significant difference in LBM between supplemented and control groups,[@bib29] and the other reported a significant difference in leg press peak power.[@bib31] Although not included as an outcome of the review, muscle power is highly relevant in this context, as it is dependent upon muscle mass and also declines with aging, impacting upon functional ability.[@bib44], [@bib45] This suggests that, under circumstances of lower baseline protein intake, there may be potential for an additive effect of RET and protein supplementation. This is of particular relevance to older adults who are frail or in institutionalized care, as protein intakes for these groups have been found to be lower than community-dwelling older people, at 1.0 and 0.8 g·kg^−1^·day^−1^, respectively.[@bib46]

In addition to the total daily protein intake, we may also consider the influence of protein supplementation with respect to the size of an individual dose of supplement. Acute studies have demonstrated that older adults require a bolus of at least 20 g of whey protein after resistance exercise to stimulate the MPS level above that of an exercised, unfed state,[@bib47] and that an even greater dose of 40 g is required when using a different protein source.[@bib48] The studies included in this review used a range of protein doses, some of which were at or above thresholds previously found to be effective in an acute setting to increase MPS. However, there were no consistent differences between the results of these studies compared with those using lower protein doses. Again, acute effects do not appear to translate to a chronic response. This also has implications for total protein intake recommendations for older adults conducting regular exercise, which are partially based on this acute evidence. It is recommended that older adults in this category require more protein than their inactive counterparts, and that they should consume at least 1.2 g·kg^−1^·day^−1^ including a 20 g supplement after exercise.[@bib43] However, the results from this review indicate that, from the perspective of improvements in muscle mass and function, there may not necessarily be any benefit from the increased protein intake.

The efficacy of protein supplementation in addition to RET has been addressed by previous systematic reviews, with contrasting results. Cermak et al[@bib11] found in favor of an additive effect in terms of FFM and muscle strength, concluding that protein/EAA supplementation augmented responsiveness to RET in both older and younger participants, a discrepancy most likely attributable to the different criteria used to define older populations. A mean age of at least 70 years was required for studies to be included in our review, giving an overall mean age of 77.4 years and a range of participant ages between 60 and 100 years, whereas the older cohort included in the previous review was aged between 48 and 72 years. The previous review was also restricted to only healthy participants, whereas we also included participants defined as frail or sarcopenic, and in fact only 1 study was common to both reviews.[@bib25] More recently, Finger et al[@bib15] considered the effects of RET and protein supplementation in older adults in terms of FFM, and muscle mass and strength. Again, the lower age limit was less than that of the current review at 60 years of age, and included studies with participants as young as 50 years of age. Of the 9 included studies, 5 were also included our review, with the remaining 4 excluded at either the abstract or full text screening stages due to the age criterion. Meta-analysis indicated a significant effect on FFM, which may again be a result of inclusion of younger participants. The meta-analysis is an area in which the methodology differed from the current review; previously, all studies with comparable outcomes were included in meta-analyses, however, in this review, we reviewed the similarity of study protocols based on a number of characteristics prior to meta-analysis, which indicated that very few of the studies were truly comparable. Further methodologic differences also allowed the current review to provide a more comprehensive view of the subject matter; a more extensive list of outcome measures includes measures of functional ability, which are highly relevant when considering the practical effects of an intervention, as well as a greater range of body composition outcomes. Furthermore, the eligibility criteria for the current review were less restrictive, as we did not exclude on the basis of other macronutrients in the supplement, allowing a greater number of studies to be included.

In general, the overall quality of the included studies was moderate to high, although several studies scored poorly for internal validity. In particular, approximately one-half of studies did not report blinding of all participants, and 4 failed to use any placebo in the control groups, meaning these studies may have been susceptible to performance bias.

Limitations {#sec3.1}
-----------

The greatest limitation of this review is the lack of meta-analysis data. Outcome measures showed a high degree of heterogeneity and data were not presented uniformly, and methodologic diversity was high, with variation in protein/EAA supplementation, training protocols, and duration of intervention. As a result, comparable outcome measures were limited, and differences in methodology meant that comparisons between most studies would not have been valid. Ideally, subgroup analysis would have been completed, for example for frail/sarcopenic and healthy groups, and for different distributions and timings of protein intake as the number of doses and proximity to exercise may have affected the response, but methodologic differences did not allow this. However, the vast majority of results indicate no additional effect of protein supplementation, and this did not appear to differ according to population or protocol characteristics, other than that of baseline protein intake discussed above.

The review may also be limited by the sample sizes of the included studies, some of which were relatively low and, therefore, may have lacked sufficient power to identify small differences between groups. Eight of the studies[@bib24], [@bib26], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33] reported a power calculation that deemed the sample size to be adequate, and there was no difference in terms of significant results between these and the studies that did not report a power calculation. However, the majority of these were powered for only selected outcome measures, usually body composition, meaning the sample sizes may not have been sufficient for other outcome measures; this is particularly important to consider with respect to more complex outcomes, such as measures of functional ability, which may require larger sample sizes to detect significant differences.

Conclusions {#sec4}
===========

Protein/EAA supplementation does not significantly augment the effects of progressive RET in older adults in terms of muscle strength, muscle size, body composition, or functional ability. The review does, however, support the prescription of RET regimens to maintain and increase muscle mass and strength in older populations, which may help to combat sarcopenia and frailty.

The findings also suggest that there may be an additional benefit of protein supplementation and RET programs in frail older adults who do not regularly consume sufficient protein, particularly those in institutionalized care. Thus, future research may consider exploring this by conducting trials placing greater emphasis on the baseline protein intake of participants. Likewise, little discussion has been given here to the protein supplement characteristics, such as the amount, timing, and distribution of ingestion, and further research may investigate these areas to fully determine whether protein supplementation could be protective against sarcopenia.

Supplementary Data {#appsec1}
==================

Supplementary File 1
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###### 

Example Search Strategy[∗](#tbl1fnlowast){ref-type="table-fn"}

  ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  1    Aged/or "aged, 80 and over"/ or frail elderly/
  2    Aging/ or longevity/
  3    (old\* adj (adult\* or age\* or people or person\* or population\*)).tw.
  4    (elder\* or old\* or ?enarian or aged or ag?ing or senior\* or geriatric\* or frail).mp.
  5    1 or 2 or 3 or 4
  6    Muscles/or muscle, skeletal/
  7    Exp Muscle Strength/
  8    Muscle Weakness/
  9    Muscular atrophy/ or sarcopenia/
  10   (musc\* adj2 (mass or strength or size or cross sectional area or CSA or thick\* or power or growth or enlarge\* or area or volume or hypertrophy)).tw.
  11   Muscle Development/
  12   Exercise therapy/ or resistance training/
  13   (weigh\* OR streng\* OR resis\*) adj2 (train\* OR exerc\* OR therap\*).mp.
  14   Hypertrophy/
  15   6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
  16   Exp Dietary Supplements/
  17   Food, Fortified/
  18   ((protein\* OR amino acid\*) adj3 supplement\*).tw.
  19   Proteins/
  20   Exp Amino Acids/
  21   Exp Dietary Proteins/
  22   16 or 17 or 18 or 19 or 20 or 21
  23   5 and 15 and 22
  24   Exp animals/ not humans.sh
  25   23 not 24
  ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------

CSA, cross-sectional area.

Ovid MEDLINE (R) search, adapted for other databases.

###### 

Study Characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, Year                                                           Participant Details   Training Details   Protein/EAA and Placebo Supplement Details                                                                                                                                                                                                                                                                                                                                          
  ---------------------------------------------------------------------- --------------------- ------------------ -------------------------------------------- ------ ------------------- --------- ---------------- --- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ----------------------------------------- ---------------------------------------------- ---------------
  Fiatarone et al, 1994[@bib21]                                          50                    86.7               Y                                            NA     3 d/wk × 10 wk      LL        80% 1-RM         N   Soy-based                                                                                                                                                           Daily           Evening                                   15 g approx.                                   Water

  Godard et al, 2002[@bib22]                                             17                    71.5               N                                            1.14   3 d/wk × 12 wk      LL        80% 1-RM         N   EAA (1.86 g L-lysine, 2.24 g L-leucine, 1.40 g L-valine, 1.86 g L-phenylalanine, 1.76 g L-threonine, 1.30 g L-histidine, 1.2 g L-isoleucine, 0.38 g L-methionine)   Daily           After training                            12 g                                           Exercise only

  Bunout et al, 2004[@bib23]                                             47                    74.1               N                                            NA     2 d/wk × 1 year     LL + UL   Light            N   Undisclosed protein                                                                                                                                                 Daily           Between meals                             15 g                                           Exercise only

  Rosendahl et al, 2006[@bib24][†](#tbl2fndagger){ref-type="table-fn"}   91                    85.2               Y                                            NA     5 d/2 wk × 13 wk    LL        8--12 RM         Y   Milk-based                                                                                                                                                          With training   After training                            7.4 g                                          CHO

  Verdijk et al, 2009[@bib25]                                            28                    72.0               N                                            1.10   3 d/wk × 12 wk      LL        60%--80% 1-RM    N   Casein                                                                                                                                                              With training   10 g before, 10 g after training          20 g                                           Water

  Zak et al, 2009[@bib26]                                                40                    78.7               Y                                            NA     5 d/wk × 7 wk       LL        80% 1-RM         Y   Undisclosed protein                                                                                                                                                 With training   Before training                           12 g approx.                                   Water

  Kim et al, 2012[@bib28]                                                77                    79.2               Y                                            NA     2 d/wk × 3 months   LL + UL   Moderate         Y   EAA (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, 5.5% other)                                                  Daily           Twice daily                               6 g                                            Exercise only

  Tieland et al, 2012[@bib29]                                            62                    78.5               Y                                            1.00   2 d/wk × 24 wk      LL + UL   50%--75%\        N   Milk-based                                                                                                                                                          Daily           15 g after breakfast, 15 g after lunch    30 g                                           CHO
                                                                                                                                                                                                    1-RM                                                                                                                                                                                                                                                                                              

  Arnarson et al, 2013[@bib30]                                           161                   73.9               N                                            1.00   3 d/wk × 12 wk      LL + UL   75%--80% 1-RM    N   Whey                                                                                                                                                                With training   After training                            20 g                                           CHO

  Chalé et al, 2013[@bib31]                                              80                    77.7               Y                                            0.97   3 d/wk × 6 months   LL + UL   80% 1-RM         N   Whey                                                                                                                                                                Daily           20 g after breakfast, 20 g after dinner   40 g                                           CHO

  Leenders et al, 2013[@bib32]                                           60                    70.0               N                                            1.15   3 d/wk × 24 wk      LL + UL   60%--80% 1-RM    N   Milk-based (80% Casein, 20% Whey)                                                                                                                                   Daily           After breakfast                           15 g                                           CHO

  Daly et al, 2014[@bib33]                                               100                   72.8               N                                            1.08   2 d/wk × 4 months   LL + UL   Moderate         Y   Red meat                                                                                                                                                            6 d/wk          Meals, after training                     45 g[‡](#tbl2fnddagger){ref-type="table-fn"}   CHO

  Franzke et al, 2015[@bib34]                                            64                    82.7               N                                            NA     2 d/wk × 6 months   LL + UL   Light to heavy   N   Whey                                                                                                                                                                Daily           Morning and after training                20.7 g                                         Exercise only

  Mitchell et al, 2015[@bib35]                                           16                    74.4               N                                            NA     3 d/wk × 12 wk      LL + UL   75%--85% 1-RM    N   Chocolate milk                                                                                                                                                      Daily           After breakfast or after training         14 g                                           Placebo drink

  Trabal et al, 2015[@bib36]                                             24                    84.5               N                                            1.20   3 d/wk × 12 wk      LL        65% 1-RM         Y   Leucine                                                                                                                                                             Daily           5 g after lunch, 5 g after dinner         10 g                                           CHO
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1-RM, 1-repetition maximum; CHO, carbohydrate; d, days; LL, lower limb; N, no; RT, resistance training; UL, upper limb; wk, weeks; Y, yes.

NA indicates studies did not report baseline protein intake.

Rosendahl et al 2006[@bib24] includes Carlsson et al, 2011.[@bib27]

Approximately 220 g (raw weight) or 160 g (cooked weight) lean red meat equated to 45 g protein.

###### 

PEDro Scale for Assessment of Study Quality

  Author, Year                                                                                                                                                                                                             Fiatarone et al, 1994[@bib23]   Godard et al, 2002[@bib22]   Bunout et al, 2004[@bib23]   Rosendahl et al, 2006[@bib24][∗](#tbl3fnlowast){ref-type="table-fn"}   Verdijk et al, 2009[@bib25]   Zak et al, 2009[@bib26]   Kim et al, 2012[@bib28]   Tieland et al, 2012[@bib29]   Arnarson et al, 2013[@bib30]   Chale et al, 2013[@bib31]   Leenders et al, 2013[@bib32]   Daly et al, 2014[@bib33]   Franzke et al, 2015[@bib34]   Mitchell et al, 2015[@bib35]   Trabal et al, 2015[@bib36]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------- ---------------------------- ---------------------------- ---------------------------------------------------------------------- ----------------------------- ------------------------- ------------------------- ----------------------------- ------------------------------ --------------------------- ------------------------------ -------------------------- ----------------------------- ------------------------------ ----------------------------
  1\. Eligibility criteria were specified                                                                                                                                                                                  Y                               Y                            Y                            Y                                                                      Y                             Y                         Y                         Y                             Y                              Y                           Y                              Y                          Y                             Y                              Y
  2\. Participants were randomly allocated to groups                                                                                                                                                                       Y                               Y                            Y                            Y                                                                      Y                             Y                         Y                         Y                             Y                              Y                           Y                              Y                          Y                             Y                              Y
  3\. Allocation was concealed                                                                                                                                                                                             N                               N                            N                            Y                                                                      N                             N                         Y                         Y                             Y                              Y                           Y                              Y                          N                             N                              N
  4\. The groups were similar at baseline regarding the most important prognostic indicators                                                                                                                               Y                               Y                            Y                            Y                                                                      Y                             Y                         Y                         Y                             Y                              Y                           N                              Y                          Y                             Y                              Y
  5\. There was blinding of all participants                                                                                                                                                                               N                               N                            N                            N                                                                      Y                             N                         N                         Y                             Y                              Y                           Y                              N                          N                             Y                              Y
  6\. There was blinding of all therapists who administered the therapy                                                                                                                                                    N                               N                            N                            N                                                                      N                             Y                         N                         Y                             Y                              Y                           Y                              N                          Y                             N                              Y
  7\. There was blinding of all assessors who measured at least 1 key outcome                                                                                                                                              Y                               N                            N                            Y                                                                      Y                             Y                         Y                         N                             Y                              Y                           Y                              N                          Y                             N                              N
  8\. Measures of at least 1 key outcome were obtained from more than 85% of the participants initially allocated to groups                                                                                                Y                               N                            N                            Y                                                                      Y                             Y                         Y                         Y                             Y                              Y                           Y                              Y                          N                             Y                              N
  9\. All participants for whom outcomes were available received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analyzed by "intention to treat"   Y                               N                            N                            Y                                                                      Y                             N                         N                         Y                             Y                              Y                           N                              Y                          N                             N                              N
  Internal Validity                                                                                                                                                                                                        5                               2                            2                            6                                                                      6                             5                         5                         7                             8                              8                           6                              5                          4                             4                              4
  10\. The results of between-group statistical comparisons are reported for at least 1 key outcome                                                                                                                        Y                               Y                            Y                            Y                                                                      Y                             Y                         Y                         Y                             Y                              Y                           Y                              Y                          Y                             Y                              Y
  11\. The study provides both point measures of variability for at least 1 key outcome                                                                                                                                    Y                               Y                            Y                            Y                                                                      Y                             Y                         Y                         Y                             Y                              Y                           Y                              Y                          Y                             Y                              Y
  Statistical Reporting                                                                                                                                                                                                    2                               2                            2                            2                                                                      2                             2                         2                         2                             2                              2                           2                              2                          2                             2                              2
   Score/10 (Criterion 1 is not used to calculate PEDro score)                                                                                                                                                             7                               4                            4                            8                                                                      8                             7                         7                         9                             10                             10                          8                              7                          6                             6                              6

N, criterion satisfied; PEDro, Physiotherapy Evidence Database; Y, criterion not satisfied.

Rosendahl et al, 2006[@bib24] includes Carlsson et al, 2011.[@bib27]

###### 

Summary of Outcome Measures and Significant Results

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, Year                                                           Outcome Measures                                                       Significant Protein Effect                                                                          
  ---------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------
  Fiatarone et al, 1994[@bib21]                                          Muscle strength                                                        1-RM leg strength (sum of L/R knee and hip extensors)                                               NS[∗](#tbl4fnlowast){ref-type="table-fn"}

  Muscle size                                                            Thigh muscle CSA                                                                                                                                                           

  Functional ability                                                     Self-paced gait velocity                                                                                                                                                   

  Godard et al 2002,[@bib22]                                             Muscle strength                                                        Knee extensor isometric and isokinetic MVC; 1-RM bilateral knee extension                           NS

  Muscle size                                                            Right thigh whole muscle CSA                                                                                                                                               

  Bunout et al, 2004[@bib23]                                             Muscle strength                                                        L/R bicep isometric strength; L/R knee extensor isometric strength; L/R handgrip strength           RH grip strength (*P* = .031)

  Muscle size                                                            Midarm, hip, and calf circumference                                                                                                                                        

  Functional ability                                                     12-minute walk capacity                                                                                                                                                    

  Body composition                                                       FFM; FM                                                                                                                                                                    

  Rosendahl et al, 2006[@bib24][†](#tbl4fndagger){ref-type="table-fn"}   Muscle strength                                                        1-RM leg press                                                                                      NS

  Functional ability                                                     Balance test; self-paced and maximum gait velocity; chair-stand test                                                                                                       

  Verdijk et al, 2009[@bib25]                                            Muscle strength                                                        1-RM leg press; 1-RM leg extension                                                                  NS

  Muscle size                                                            Quadriceps muscle CSA                                                                                                                                                      

  Body composition                                                       LBM; FM; % FM; leg LTM; leg % FM                                                                                                                                           

  Zak et al, 2009[@bib26]                                                Muscle strength                                                        L/R 1-RM knee extension; L/R 1-RM knee flexion; L/R 1-RM hip extension; L/R 1-RM hip knee flexion   NS

  Functional ability                                                     6-minute walk capacity; POMA                                                                                                                                               

  Carlsson et al, 2011[@bib27][†](#tbl4fndagger){ref-type="table-fn"}    Body composition                                                       MM (intra cellular water proxy)                                                                     NS

  Kim et al, 2012[@bib28]                                                Muscle strength                                                        Knee extension                                                                                      Knee extension strength\
                                                                                                                                                                                                                                                    (*P* = .01)

  Functional ability                                                     Self-paced and maximum gait velocity                                                                                                                                       

  Body composition                                                       Total MM; appendicular MM; leg MM                                                                                                                                          

  Tieland et al, 2012[@bib29]                                            Muscle strength                                                        1-RM leg press; 1-RM leg extension; handgrip strength                                               LBM (*P* = .006);\
                                                                                                                                                                                                                                                    appendicular LTM (*P* \< .001); FM (*P* = .001)

  Functional ability                                                     SPPB                                                                                                                                                                       

  Body composition                                                       LBM; FM; appendicular LTM                                                                                                                                                  

  Arnarson et al, 2013[@bib30]                                           Muscle strength                                                        Knee extensor isometric MVC                                                                         NS

  Functional ability                                                     Timed up-and-go; 6-minute walk capacity                                                                                                                                    

  Body composition                                                       LBM; appendicular LTM                                                                                                                                                      

  Chalé et al, 2013[@bib31]                                              Muscle strength                                                        1-RM leg press; L/R 1-RM knee extension                                                             NS

  Muscle size                                                            Total muscle CSA of nondominant thigh                                                                                                                                      

  Functional ability                                                     SPPB; stair climb speed; ×10 chair rise time; gait velocity                                                                                                                

  Body composition                                                       LBM; FM                                                                                                                                                                    

  Leenders et al, 2013[@bib32]                                           Muscle strength                                                        1-RM leg press; 1-RM leg extension; handgrip strength                                               NS

  Muscle size                                                            Quadriceps muscle CSA                                                                                                                                                      

  Functional ability                                                     5x chair rise time                                                                                                                                                         

  Body composition                                                       LBM; FM; % FM; leg LTM; leg FM                                                                                                                                             

  Daly et al, 2014[@bib33]                                               Muscle strength                                                        1-RM leg extension                                                                                  Leg extension strength\
                                                                                                                                                                                                                                                    (*P* = .010);\
                                                                                                                                                                                                                                                    LBM (*P* = .007);\
                                                                                                                                                                                                                                                    leg LTM (*P* \< .05)

  Muscle size                                                            Femur muscle CSA                                                                                                                                                           

  Functional ability                                                     4-square step test; timed up-and-go; 30-second chair rise test                                                                                                             

  Body composition                                                       Total body FM; body fat percentage; LBM; arm LTM, leg LTM                                                                                                                  

  Franzke et al, 2015[@bib34]                                            Muscle strength                                                        Handgrip strength                                                                                   NS

  Functional ability                                                     6-minute walk capacity; 30-second chair rise test                                                                                                                          

  Mitchell et al, 2015[@bib35]                                           Muscle strength                                                        1-RM leg press; 1-RM leg extension; 1-RM chest press; Knee extension isometric MVC                  NS

  Trabal et al, 2015[@bib36]                                             Muscle strength                                                        Leg flexion overcoming isometric strength                                                           Leg flexion (*P* = .056)

  Muscle size                                                            Mid upper arm muscle area; triceps skinfold; calf circumference                                                                                                            

  Functional ability                                                     Balance test; TUG; ×5 chair rise time; 4m walk time                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1-RM, 1-repetition maximum; CSA, cross-sectional area; L/R, right and left; MVC, maximum voluntary contraction; RH, right hand; POMA, Performance Oriented Mobility Assessment; SPPB, Short Physical Performance Battery.

NS indicates no significant differences between the RET and protein supplement and RET only groups. For significant results, the outcome measure and *P* value, where available, are reported.

Rosendahl et al 2006[@bib24] and Carlsson et al 2011[@bib27] report results from the same study, presented separately as report different outcome measures.
